


Name	Mohamed Kharfan-Dabaja, MD, MBA, FACP	
Current Position	Director of Blood and Marrow Transplantation and Cellular Therapies Program Mayo Clinic Jacksonville, FL, USA	
Country	United States of America	
Major Field	Blood and Marrow Transplantation and Cellular Therapies	

Educational Background

Undergraduate: American University of Beirut (Beirut, Lebanon)
Major: Biology
Degree: Bachelor of Sciences
Month/year degree conferred: June 1991

Medical School: American University of Beirut (Beirut, Lebanon)
Degree: Doctor of Medicine (M.D.)
Month/year degree conferred: June 1995

Training:

Internship in transitional (rotating) medicine
Institution: American University of Beirut Medical Center
Location: Beirut, Lebanon
Rank: PGY-1
From (month/year) to (month/year): July 1995 – June 1996

Internship and residency in Internal Medicine
Institution: Good Samaritan Hospital/affiliated with the Johns Hopkins Univ.
Location: Baltimore, Maryland, USA
Rank: PGY-1, PGY-2, PGY-3
From (month/year) to (month/year): July 1996 – June 1999

Fellowship in Hematology and Medical Oncology
Institution: University of Miami/Jackson Memorial Hospital and Sylvester Comprehensive Cancer Center
Location: Miami, Florida, USA
Rank: PGY-4, PGY-5, PGY-6
From (month/year) to (month/year): July 1999- June 2002

Other Graduate Education

Master in Business Administration (exec)
University of South Florida (USF), MUMA College of Business
Location: Tampa, Florida
From (month/year) to (month/year): 08/2014-04/2016
Class of 2016
Degree: Masters in Business Administration (MBA)
Date degree granted: May 07, 2016



Professional Experience

Assistant Professor of Medicine

Institution: University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center

Oklahoma City, OK, USA

August 2002- September 2005

Assistant Professor of Medicine

Institution: University of South Florida College of Medicine/ Moffitt Cancer Center

Tampa, FL, USA

September 2005-June 2008

Associate Professor of Medicine

Institution: University of South Florida College of Medicine/ Moffitt Cancer Center

Tampa, FL, USA

July 2008-August 2010

Associate Professor of Clinical Medicine

Institution: American University of Beirut Faculty of Medicine

Beirut, Lebanon

September 2010-Sept 2012

Professor of Oncologic Sciences and Senior Member

Institution: Moffitt Cancer Center/University of South Florida Morsani College of Medicine

September 2012-December 18, 2017

Tenure, July 01, 2016-December 18, 2017

Institution: Moffitt Cancer Center

Senior Associate Consultant

Institution: Mayo Clinic

December 19, 2017- December 2020

Consultant

Institution: Mayo Clinic

December 2020-ongoing

Professor of Medicine

Institution: Mayo Clinic

May 1, 2018- ongoing

Other Experience and Professional Memberships

- Elected to membership of the *Alpha Omega Alpha* Honor Medical Society, 2011-ongoing
- Elected to membership of the *Phi Kappa Phi* Honor Society, March 2015-ongoing
- Elected to membership of the honorary *Betta Gamma Sigma* Society, April 2016-ongoing

Membership in professional societies

- American College of Physicians (Fellow)
Dates: 1997-present
- Member, American Society of Hematology
Dates: 2001-present
- Member, American Society for Blood and Marrow Transplantation
Dates: 2006-present
- Member, European Society for Blood and Marrow Transplantation
Dates: 2014-ongoing

Main Scientific Publications

In the past 5 years (from more recent):

1. Melody M, Gandhi S, Saunders H, Abdel-Rahman Z, Hastings J, Lengerke Diaz P, Gannon N, Truong T, Hathcock M, Khurana A, Johnston P, Ansell S, Bennani N, Paludo J, Villasboas Bisnieta J, Wang Y, Rosenthal A, Foran J, Ayala E, Murthy HS, Roy V, Castro JE, Lin Y, **Kharfan-Dabaja MA**. Incidence of thrombosis in relapsed/refractory B-Cell Lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. *Leuk Lymphoma*. 2022 Feb 3:1-6. doi: 10.1080/10428194.2022.2030475. Online ahead of print
2. Badar T, Manna A, Gadd ME, **Kharfan-Dabaja MA**, Qin H. Prospect of CAR T-cell therapy in acute myeloid leukemia. *Expert Opin Investig Drugs*. 2022 Jan 20 [Epub Ahead of Print].
3. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Mueller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, **Kharfan-Dabaja M**, Newsome S, Degtyarev E, Awasthi R, del Corral C, Andreola G, Masood A, Schuster SJ, Jaeger U, Borchmann P, Westin JR. Tisagenlecleucel Versus Standard of Care in Second-Line Aggressive B-Cell Lymphoma. *N Engl J Med*. 2021 Dec 14. doi: 10.1056/NEJMoa2116596. Online ahead of print.

4. **Kharfan-Dabaja MA**, Yassine F, Gadd M, Qin H. Driving out chronic lymphocytic leukemia with CAR T-cells. *Transplant Cell Ther.* 2021 Oct 14:S2666-6367(21)01297-5. doi: 10.1016/j.jtct.2021.10.005. Online ahead of print.
5. **Kharfan-Dabaja MA**, Reljic T, Kumar A, Yassine F, Keller K, Fernandez A, Murthy H, Ayala E, Aljurf M, Iqbal M. Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis. *Bone Marrow Transplant.* 2021 Oct 12. doi: 10.1038/s41409-021-01496-3. Online ahead of print.
6. Forero-Forero JV, Lengerke-Diaz PA, Felipe Moreno E, Melody M, Abdel Rahman ZH, Rosenthal AC, **Kharfan-Dabaja MA**, Castro JE. Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B cell non-Hodgkin lymphoma. *Hematol Oncol Stem Cell Ther.* 2021 Sep 20:S1658-3876(21)00084-4. doi: 10.1016/j.hemonc.2021.09.001. Online ahead of print
7. Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter GS, **Kharfan-Dabaja MA**, Hamadani M. Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. *Blood.* 2021 Sep 27:blood.2021013289. doi: 10.1182/blood.2021013289. Online ahead of print.
8. Abdel Rahman ZH, Heckman MG, Anagnostou T, White LJ, Kloft-Nelson SM, Knudson RA, Alkhateeb HB, Sproat LZ, Khera N, Murthy HS, Ayala E, Hogan WJ, Roy V, Peterson JF, **Kharfan-Dabaja MA**, Ketterling RP, Litzow MR, Patnaik M, Greipp PT, Foran JM. Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer J.* 2021 Sep 21;11(9):156. doi: 10.1038/s41408-021-00538-9
9. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, **Kharfan-Dabaja MA**, Locke FL, Shadman M, Hill B, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith S, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma. *Transplant Cell Ther.* 2021 Sep;27(9):720-728 (simultaneous publication in Bone Marrow Transplant)
10. Herrera AF, Ahn KW, Litovich C, Chen S, Assal A, Bashir Q, Bayer R-L, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Lachance S, Langston A, Mattar B, Maziarz R, McGuirk J, Milan M, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, **Kharfan-Dabaja MA**, Hamadani M. Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome. *Blood Adv.* 2021 Sep 8:bloodadvances.2021004865. doi: 10.1182/bloodadvances.2021004865. Online ahead of print.
11. **Kharfan-Dabaja MA**, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs L, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFillip Z, Dholaria B, El-Jawahri A, Fanning S, Faint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales M-A, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw P, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing definitions

- of hematopoietic recovery, graft rejection, graft failure, poor graft function and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2021 Aug;27(8):642-649
12. Yassine F, Sandoval-Sus J, Ayala E, Hamadani M, Chavez J, **Kharfan-Dabaja MA**. Cellular Therapies for Mantle Cell Lymphoma. *Transplant Cell Ther.* 2021 May;27(5):363-370.
 13. **Kharfan-Dabaja MA**, Labopin M, Bazarbachi A, Ciceri F, Finke J, Benedetto B, Bornhauser M, Gedde-Dahl T, Labussière-Wallet H, Niittyvuopio R, Valerius T, Angelucci E, Brecht A, Caballero D, Kuball J, Potter V, Schmid C, Tischer J, Zuckerman T, Benedetti F, Blaise D, Diez-Martin JL, Sanz J, Ruggeri A, Brissot E, Savani BN, Giebel S, Nagler A, Mohty M. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. *Bone Marrow Transplant.* 2021 Apr 30. doi: 10.1038/s41409-021-01317-7. Online ahead of print.
 14. Scordo M, Wang TP, Ahn KW, Chen S, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez AM, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Geethakumari PR, Rezvani AR, Riedell P, Seo S, Shah NN, Solh M, Yared JA, **Kharfan-Dabaja MA**, Herrera A, Hamadani M, Sauter GS. Outcomes associated with Thiotepa-Based Conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. *JAMA Oncol.* 2021 May 6. doi: 10.1001/jamaoncol.2021.1074. Online ahead of print.
 15. **Kharfan-Dabaja MA**, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty M. Second Allogeneic Hematopoietic Cell Transplantation Using HLA-Matched Unrelated vs. T-cell Replete Haploidentical Donor and Survival in Relapsed Acute Myeloid Leukemia. *Br J Haematol.* 2021 Apr 10. doi: 10.1111/bjh.17426. Online ahead of print.
 16. Yassine F, Reljic T, Alhaj Moustafa M, Iqbal M, Murthy HS, Kumar A, **Kharfan-Dabaja MA**. Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. *Hematol Oncol Stem Cell Ther.* 2021 Mar 11:S1658-3876(21)00028-5. doi: 10.1016/j.hemonc.2021.02.003. Online ahead of print.
 17. Iqbal M, Reljic T, Corbacioglu S, de la Fuente J, Gluckman E, Kumar A, Yassine F, Ayala E, El-Jawahri A, Murthy H, Almohareb F, Hashmi S, Cappelli B, Alahmari A, Scigliuolo G, Kassim A, Aljurf M, **Kharfan-Dabaja MA**. Systematic review/meta-analysis on efficacy of allogeneic HCT in sickle cell disease: an international effort on behalf of the Pediatric Diseases Working Party of EBMT and the Sickle Cell Transplantation International Consortium. *Transplant Cell Ther.* 2021 Feb;27(2):167.e1-167.e12. doi: 10.1016/j.jtct.2020.10.007. Epub 2020 Dec 10.
 18. Melody M, Gandhi S, Abdel Rahman Z, Lengerke Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani N, Paludo J, Villasboas Bisneto J, Ayala E, Tun HW, Murthy H, Roy V, Foran J, Castro J, Lin Y, **Kharfan-Dabaja MA**. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. *Eur J Haematol.* 2021 Mar 2. doi: 10.1111/ejh.13609. Online ahead of print.
 19. Melody M, Abdel Rahman Z, Saunders H, Lengerke Diaz P, Gannon N, Rosenthal A, Ayala E, Tun H, Murthy H, Roy V, Foran J, Castro J, Guru P, **Kharfan-Dabaja MA**. C-reactive protein and ferritin

- levels and length of ICU stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. *Hematol Oncol Stem Cell Ther.* 2020 Oct 13; S1658-3876(20)30151-5. doi: 10.1016/j.hemonc.2020.09.004. Online ahead of print.
20. Dholaria B, Savani B, Hamilton BK, Oran B, Liu HD, Tallman M, Ciurea SO, Holtzman NG, Phillips GL, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, Al Chaer F, Shah N, Hashmi SK, **Kharfan-Dabaja MA**, DeFillip Z, Aljurf M, Alshaibani A, Inamoto Y, Jain T, Majhail N, Perales M-A, Mohty M, Hamadani M, Carpenter PA, Nagler A. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant.* 2020 Sep 20;S1083-8791(20)30584-X. doi: 10.1016/j.bbmt.2020.09.020. Online ahead of print.
21. **Kharfan-Dabaja MA**, Cherry M. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. *Hematol Oncol Clin North Am.* 2020 Jun;34(3):621-629. doi: 10.1016/j.hoc.2020.01.009. Epub 2020 Mar 17.
22. Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Abou Dalle I, Dohner H, Esteve J, Floisand Y, Giebel S, Gilleece M, Gorin N-C, Jabbour E, Aljurf M, Kantarjian H, **Kharfan-Dabaja M**, Labopin M, Lanza F, Malard F, Peric Z, Prebet T, Ravandi F, Ruggeri A, Sanz J, Schmid C, Shouval R, Spyridonidis A, Versluis J, Vey N, Savani BN, Nagler A, Mohty M. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica.* 2020 Apr 2. pii: haematol.2019.243410. doi: 10.3324/haematol.2019.243410. [Epub ahead of print]
23. Schmidt S, Liu Y, Hu Z-H, Williams KM, Lazarus HM, Vij R, **Kharfan-Dabaja MA**, Orti G, Wiernek PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Ulrike Bacher V, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gegis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter-Chakrabarty J, Saber W. Tyrosine Kinase Inhibitors (TKIs) are superior to Donor Lymphocyte Infusion (DLI) for Relapse of Chronic Myeloid Leukemia (CML) Post Hematopoietic Cell Transplantation (HCT). *Biol Blood Marrow Transplant.* 2020 Feb 13. pii: S1083-8791(20)30090-2. doi: 10.1016/j.bbmt.2020.02.006. [Epub ahead of print]
24. Fatobene G, Rocha V, St. Martin A, Hamadani M, Robinson S, Bashey A, Boumedil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, **Kharfan-Dabaja M**, Labussière-Wallet H, Moraleta J, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang M-J, Gluckman E, Montoto S, Eapen M. Non-Myeloablative Alternative Donor Transplantation for Hodgkin and non-Hodgkin. Lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR. *J Clin Oncol.* 2020 Feb 7;JCO1902408. doi: 10.1200/JCO.19.02408. [Epub ahead of print]
25. Lazaryan A, Dolan M, Zhang MJ, Wang HL, **Kharfan-Dabaja MA**, Marks DI, Bejanyan N, Copelan E, Majhail N, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsayy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Castillo Caro P, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, de Lima M, Litzow M, Bachanova V,

- Weisdorf D. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. *Haematologica*. 2019 Sep 26. pii: haematol.2019.220756. doi: 10.3324/haematol.2019.220756. [Epub ahead of print].
26. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri K, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani B, Schuster SJ, **Kharfan-Dabaja MA***, **Perales MA***, **Lin Y***. Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] ***Shared senior authorship**
27. Moukalled NM, **Kharfan-Dabaja MA**. What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? *Bone Marrow Transplant*. 2019 Jun 3. doi: 10.1038/s41409-019-0584-3. [Epub ahead of print]
28. Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, **Kharfan-Dabaja MA**. Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis. *Biol Blood Marrow Transplant*. 2019 May 25. pii: S1083-8791(19)30338-6. doi: 10.1016/j.bbmt.2019.05.027. [Epub ahead of print]
29. **Kharfan-Dabaja MA**, Pemmaraju N, Mohty M. Therapeutic approaches for blastic plasmacytoid dendritic cell neoplasm: allogeneic hematopoietic cell transplantation and novel therapies. *Clinical Hematology International*. 2019; 1 (1): 2-9.
30. Aljurf M, Weisdorf D, Alfraih F, Szer J, Muller C, Confer D, Hashmi S, Kroger N, Shaw B, Greinix H, **Kharfan-Dabaja MA**, Foeken L, Seber A, Ahmed S, El-Jawhari A, Alawammi M, Handali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Koderia Y, Horowitz M, Niederwieser D, El Fakih R. Worldwide Network for Blood & Marrow Transplantation (WBMT) special Article, Challenges Facing Emerging Alternate Donor Registries. *Bone Marrow Transplant*. 2019 Feb 18. doi: 10.1038/s41409-019-0476-6. [Epub ahead of print]
31. Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg J, Inwards D, Herrera A, **Kharfan-Dabaja MA**, Reddy N, Montoto S, Robinson SP, Abu Talib S, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales M-A, Carpenter P, Savani BN, Hamadani M. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. *JAMA Oncol*. 2019 Feb 28. doi: 10.1001/jamaoncol.2018.6278. [Epub ahead of print]
32. **Kharfan-Dabaja MA**, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M. Treatment of post-allograft relapsed AML with a second allogeneic HCT or DLI: An observational study of the Acute Leukemia Working Party of EBMT. *JAMA Oncol*. 2018 Jul 12. doi: 10.1001/jamaoncol.2018.2091. [Epub ahead of print]

-
33. **Kharfan-Dabaja MA**, Reljic T, Murthy H, Ayala E, Kumar A. Allogeneic Hematopoietic Cell Transplantation is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: a Systematic Review/Meta-analysis. *Clin Lymphoma Myeloma Leuk*. 2018 Aug 2. pii: S2152-2650(18)30595-0. doi: 10.1016/j.clml.2018.07.295. [Epub ahead of print]
34. Ayala E, Chavez JC, Gomez A, Sleiman E, Kumar A, **Kharfan-Dabaja MA**. Feasibility and efficacy of high-dose chemotherapy and autologous hematopoietic cell transplantation for HIV-associated lymphoma: a single-institution experience. *Clin Lymphoma Myeloma Leuk*. 2018 May 23. pii: S2152-2650(18)30085-5. doi: 10.1016/j.clml.2018.05.011. [Epub ahead of print]
35. **Kharfan-Dabaja MA**, Sheets K, Kumar A, Murthy H, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J. Hypoalbuminemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. *Br J Haematol*. 2018 Jan 18. doi: 10.1111/bjh.15105. [Epub ahead of print]
36. Dholaria BR, Ayala E, Nishihori T, Sokol L, Chavez JC, Hussaini M, Kumar A, **Kharfan-Dabaja MA**. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: a single-center experience. *Leuk Res*. 2018; 67:1-5. doi: 10.1016/j.leukres.2018.01.009. [Epub ahead of print]
37. **Kharfan-Dabaja MA**, Moukalled N, Reljic T, El-Asmar J, Kumar A. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: a systematic review/meta-analysis. *Hematology Oncology Stem Cell Therapy*, 2017 Nov 26. pii: S1658-3876(17)30120-6. doi: 10.1016/j.hemonc.2017.11.001. [Epub ahead of print]
38. **Kharfan-Dabaja MA**, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske T, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi P, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Al Malki M, Shah B, Chavez J, Kumar A, Ganguly S. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in gray zone lymphoma: a US multicenter collaborative study. *Biol Blood Marrow Transplant*. 2017 Dec 7. pii: S1083-8791(17)30880-7. doi: 10.1016/j.bbmt.2017.11.033. [Epub ahead of print]
39. Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts B, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, **Kharfan-Dabaja MA**. Hypoalbuminemia at day +90 is associated with inferior non-relapse mortality and overall survival in allogeneic HCT recipients: a conformatory study. *Biol Blood Marrow Transplant*. 2017 Oct 12. pii: S1083-8791(17)30766-8. doi: 10.1016/j.bbmt.2017.09.022. [Epub ahead of print]
40. **Kharfan-Dabaja MA**, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darragh J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Efficacy of allogeneic hematopoietic cell transplantation in blastic plasmacytoid dendritic cell neoplasm: a North American multicenter collaborative study. *Br J Haematol*. 2017 Oct 4. doi: 10.1111/bjh.14954. [Epub ahead of print]
41. **Kharfan-Dabaja MA**, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Horwitz S, Chavez J, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanalle MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter P, Savani BN. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell and NK/T-cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2017 Aug 7. pii: S1083-8791(17)30623-7. doi: 10.1016/j.bbmt.2017.07.027. [Epub ahead of print]
42. **Kharfan-Dabaja MA**, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A,
-

Anasetti C, Padron E. *TP53* and *IDH2* somatic mutations are associated with inferior survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. ***Clin Lymphoma Myeloma Leuk.*** 2017 Jun 16. pii: S2152-2650(17)30590-6. doi: 10.1016/j.clml.2017.06.003. [Epub ahead of print]

43. **Kharfan-Dabaja MA**, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Orti G, Barba P, Valcarel D, Esquirol A, Martino R, Piñana JL, Solano C, Pidala J, Anasetti C, Peres-Simon JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. ***Bone Marrow Transplant.*** 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.
-
-